DK2182960T3 - Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed - Google Patents

Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed

Info

Publication number
DK2182960T3
DK2182960T3 DK08794808.9T DK08794808T DK2182960T3 DK 2182960 T3 DK2182960 T3 DK 2182960T3 DK 08794808 T DK08794808 T DK 08794808T DK 2182960 T3 DK2182960 T3 DK 2182960T3
Authority
DK
Denmark
Prior art keywords
slackness
furrows
formulations
compounds
methods
Prior art date
Application number
DK08794808.9T
Other languages
English (en)
Inventor
Jack Dejovin
Original Assignee
Galderma Lab Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Lab Inc filed Critical Galderma Lab Inc
Application granted granted Critical
Publication of DK2182960T3 publication Critical patent/DK2182960T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/40—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing nitrogen
    • A61K8/41—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/494—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with more than one nitrogen as the only hetero atom
    • A61K8/4946—Imidazoles or their condensed derivatives, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q17/00—Barrier preparations; Preparations brought into direct contact with the skin for affording protection against external influences, e.g. sunlight, X-rays or other harmful rays, corrosive materials, bacteria or insect stings
    • A61Q17/04—Topical preparations for affording protection against sunlight or other radiation; Topical sun tanning preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/08—Anti-ageing preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/70—Biological properties of the composition as a whole

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Birds (AREA)
  • Gerontology & Geriatric Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Cosmetics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DK08794808.9T 2007-07-27 2008-07-28 Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed DK2182960T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US95229807P 2007-07-27 2007-07-27
PCT/US2008/009117 WO2009017705A1 (en) 2007-07-27 2008-07-28 Compounds, formulations, and methods for reducing skin wrinkles, creasing and sagging

Publications (1)

Publication Number Publication Date
DK2182960T3 true DK2182960T3 (da) 2014-05-26

Family

ID=40304650

Family Applications (1)

Application Number Title Priority Date Filing Date
DK08794808.9T DK2182960T3 (da) 2007-07-27 2008-07-28 Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed

Country Status (10)

Country Link
US (3) US20090060852A1 (da)
EP (1) EP2182960B1 (da)
CY (1) CY1115130T1 (da)
DK (1) DK2182960T3 (da)
ES (1) ES2463717T3 (da)
HR (1) HRP20140397T1 (da)
PL (1) PL2182960T3 (da)
PT (1) PT2182960E (da)
SI (1) SI2182960T1 (da)
WO (1) WO2009017705A1 (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8410102B2 (en) 2003-05-27 2013-04-02 Galderma Laboratories Inc. Methods and compositions for treating or preventing erythema
US7812049B2 (en) 2004-01-22 2010-10-12 Vicept Therapeutics, Inc. Method and therapeutic/cosmetic topical compositions for the treatment of rosacea and skin erythema using α1-adrenoceptor agonists
PL2182960T3 (pl) 2007-07-27 2014-08-29 Galderma Laboratories Inc Związki, preparaty i sposoby zmniejszania zmarszczek, zwiotczenia i pofałdowania skóry
US8114898B2 (en) 2007-11-16 2012-02-14 Allergan, Inc. Compositions and methods for treating purpura
CA2749750C (en) * 2008-04-15 2014-01-28 Immanence Integrale Dermo Correction Inc. Skin care compositions and methods of use thereof
US8357795B2 (en) 2008-08-04 2013-01-22 Allergan, Inc. Hyaluronic acid-based gels including lidocaine
WO2010115081A2 (en) * 2009-04-02 2010-10-07 Allergan, Inc. Hair-like shaped hydrogels for soft tissue augmentation
WO2010136594A2 (en) 2009-05-29 2010-12-02 Symatese Injectable combination of adrenergic receptor agonists with fillers, for decreasing skin reactions due to injection
US20110172180A1 (en) 2010-01-13 2011-07-14 Allergan Industrie. Sas Heat stable hyaluronic acid compositions for dermatological use
US9114188B2 (en) 2010-01-13 2015-08-25 Allergan, Industrie, S.A.S. Stable hydrogel compositions including additives
CN106038476B (zh) 2010-03-26 2020-04-17 盖尔德马研究及发展公司 安全和有效治疗红斑的改进的方法和组合物
US8916562B2 (en) 2010-03-26 2014-12-23 Galderma Research & Development Snc Methods and compositions for safe and effective treatment of telangiectasia
US20120076738A1 (en) * 2010-09-28 2012-03-29 Michael Graeber Combination treatment for dermatological conditions
US8053427B1 (en) * 2010-10-21 2011-11-08 Galderma R&D SNC Brimonidine gel composition
EP2629757A2 (en) 2010-10-21 2013-08-28 Galderma S.A. Brimonidine gel compositions and methods of use
CA2850964C (en) 2011-10-05 2021-02-02 Jennifer L. Sanders Methods and compositions for treating foot or hand pain
WO2014146994A1 (en) * 2013-03-20 2014-09-25 F. Hoffmann-La Roche Ag Urea derivatives and their use as fatty-acid binding protein (fabp) inhibitors
ES2693771T3 (es) * 2014-01-29 2018-12-13 Bristol-Myers Squibb Company Inhibidores de aril lactama quinasa
KR20220119066A (ko) * 2019-12-19 2022-08-26 스키노시브 접착성 광보호성 화합물 및 이의 용도

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4164570A (en) * 1973-09-24 1979-08-14 David Clough Stabilized aqueous catecholamine solutions
US4285967A (en) * 1978-06-30 1981-08-25 Estee Lauder Inc. Cosmetic preparation for reducing redness of blemishes
US4256763A (en) * 1978-09-19 1981-03-17 Mchugh John E Treatment of herpes simplex infections and acne
US5256652A (en) * 1987-11-12 1993-10-26 Pharmedic Co. Topical compositions and methods for treatment of male impotence
FR2648709A1 (fr) * 1989-06-23 1990-12-28 Boehringer Ingelheim France Nouvelle utilisation de derives de 1-phenyl-2-aminoethanol en tant que moyens cicatrisants
US5012797A (en) * 1990-01-08 1991-05-07 Montefiore Hospital Association Of Western Pennsylvania Method for removing skin wrinkles
US5254331A (en) * 1991-09-12 1993-10-19 Chanel, Inc. Skin cream composition
WO1993021899A1 (en) * 1992-05-05 1993-11-11 The Procter & Gamble Company Acne treating composition
US5643586A (en) * 1995-04-27 1997-07-01 Perricone; Nicholas V. Topical compositions and methods for treatment of skin damage and aging using catecholamines and related compounds
DE29612123U1 (de) * 1996-07-11 1996-09-12 Kafl, Johann, 83730 Fischbachau Dermapermeables (hautdurchlässiges) Gel (Salbe) zur subcutanen Lipidmetabolisierung (Unterhautfettverbrennung) und Behandlung von Cellulite
US5910312A (en) * 1996-10-09 1999-06-08 Ideal Ideas, Inc. Acne treatment composition with vasoconstrictor
US5916574A (en) * 1996-10-09 1999-06-29 Ideal Ideas, Inc. Method of treating natural poison skin conditions
CN1235559C (zh) * 1998-03-11 2006-01-11 株式会社创研 皮肤水分保持能力的改善剂
US5989528A (en) * 1998-07-30 1999-11-23 The Procter & Gamble Company Sunscreen compositions
US6444647B1 (en) * 1999-04-19 2002-09-03 The Procter & Gamble Company Skin care compositions containing combination of skin care actives
US20040266776A1 (en) * 2003-06-25 2004-12-30 Gil Daniel W. Methods of preventing and reducing the severity of stress-associated conditions
JP2004196759A (ja) * 2002-12-18 2004-07-15 Takashi Suzuki ビタミンｋ類とビタミンｅ複合の美肌化粧料
US7439241B2 (en) * 2003-05-27 2008-10-21 Galderma Laboratories, Inc. Compounds, formulations, and methods for treating or preventing rosacea
US20050020600A1 (en) * 2003-07-23 2005-01-27 Scherer Warren J. Methods of treating cutaneous flushing using selective alpha-2-adrenergic receptor agonists
US7288263B2 (en) * 2004-09-13 2007-10-30 Evera Laboratories, Llc Compositions and methods for treatment of skin discoloration
US7776915B2 (en) * 2005-03-24 2010-08-17 Tracie Martyn International, Llc Topical formulations and methods of use
US20060275228A1 (en) * 2005-05-09 2006-12-07 Bissett Donald L Skin care compositions containing idebenone
US20070082070A1 (en) * 2005-10-11 2007-04-12 Stookey Evangeline L Treating skin disorders
US7252816B1 (en) * 2006-03-29 2007-08-07 Dow Pharmaceutical Sciences Topical acne vulgairs medication with a sunscreen
PL2182960T3 (pl) 2007-07-27 2014-08-29 Galderma Laboratories Inc Związki, preparaty i sposoby zmniejszania zmarszczek, zwiotczenia i pofałdowania skóry

Also Published As

Publication number Publication date
PT2182960E (pt) 2014-06-11
EP2182960B1 (en) 2014-03-19
SI2182960T1 (sl) 2014-07-31
US20090060852A1 (en) 2009-03-05
US8440688B2 (en) 2013-05-14
EP2182960A1 (en) 2010-05-12
US20130243837A1 (en) 2013-09-19
CY1115130T1 (el) 2016-12-14
PL2182960T3 (pl) 2014-08-29
ES2463717T3 (es) 2014-05-29
HRP20140397T1 (hr) 2014-06-20
WO2009017705A1 (en) 2009-02-05
US20110286945A1 (en) 2011-11-24
EP2182960A4 (en) 2010-10-27

Similar Documents

Publication Publication Date Title
DK2182960T3 (da) Forbindelser, formuleringer og fremgangsmåder til reducering af hudrynker, furer og slaphed
CY2022017I2 (el) Παραγωγα πυριδαζινονης
HRP20181774T1 (hr) Novi citostatski 7-deazapurinski nukleosidi
DK2300443T3 (da) Triazolderivater, der er anvendelige til behandling af sygdomme
DK3424932T3 (da) Bronophthalider til terapeutisk anvendelse
DK3428148T3 (da) Aryloazol-2-yl-cyanoethylaminoforbindelser, fremgangsmåde til fremstilling og fremgangsmåde til anvendelse deraf
DK2121139T3 (da) Formulations for cancer treatment
DK3456707T3 (da) 4-(p-quinonyl)-2-hydroxybutanamidderivater til behandling af mitokondriesygdomme
DK2222675T3 (da) 5-anilinoimidazopyridiner og fremgangsmåder til deres anvendelse
DK2358669T3 (da) Alpha-keto-persyrer og fremgangsmåder til fremstilling og anvendelse heraf
DK2209375T3 (da) Parp-inhibitorforbindelser, præparater og fremgangsmåder til anvendelse deraf
DK2229360T3 (da) Indolinonderivater og fremgangsmåde til deres fremstilling
DK2504005T3 (da) Anvendelse af 1,3-diphenylprop-2-en-1-on-derivater til behandling af lever-sygdomme
DK3058875T3 (da) System til kosmetisk behandling og billedoptagelse
EP2120569A4 (en) SPIROCHROMANONDERIVATE
DK3457135T3 (da) Behandlingsmuligheder til fabrys sygdom
BRPI0814188A2 (pt) Formulações
DK2270818T3 (da) Polyelektrolyt og fremgangsmåde til fremstilling af polyelektrolytten
NO20076533L (no) Fremgangsmåte og system for klokkedriftskompensering
EP2241332A4 (en) THERAPEUTIC AGENT AGAINST PRITURE
DK2432798T3 (da) 17-hydroxy-17-pentaflourethyl-estra-4,9(10)-dien-11-aryl-derivat, fremgangsmåde til fremstilling heraf og anvendelse heraf til behandling af sygdomme
HUE036071T2 (hu) Macitentánt tartalmazó terápiás készítmények
DK2285808T3 (da) Spiroindolderivater til behandling af parasitsygdomme
DK2117565T3 (da) Anvendelse af chitosaner til behandlingen af negleinflammatoriske sygdomme
BRPI0818598A2 (pt) agentes terapêuticos - 802